EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Clinical Course and Development of Rheumatological Diseases in Individuals With Asymptomatic Rheumatoid Factor Positivity: A Retrospective Cohort Study

Esra Dilsat Imrak

The European Research Journal · 2026-09-11 · 1-9

DOI: 10.18621/eurj.1324 ↗
AbstractBibliografische Angaben

Abstract

Objective: The clinical significance of asymptomatic rheumatoid factor (RF) positivity remains incompletely understood. This study evaluated 2-year clinical outcomes and predictive factors for disease progression in individuals with asymptomatic RF positivity. Methods: This retrospective cohort study included 88 asymptomatic RF-positive individuals followed up at 6-month intervals for 2 years. Baseline anti–cyclic citrullinated peptide (anti-CCP), antinuclear antibody, and hepatitis B/C serologies were analyzed. Statistical methods included Spearman correlation, univariate logistic regression with Firth correction, and 1-sided Fisher exact testing. Results: The mean (SD) age was 51.5 (14.9) years; 67 (76.1%) were female. Within 2 years, rheumatologic diseases developed in 14 participants (15.9%): rheumatoid arthritis (RA; n = 7), Sjögren disease (n = 5), systemic lupus erythematosus (n = 1), and undifferentiated connective tissue disease (n = 1). Baseline HBsAg positivity was 8.0% (n = 7). Anti-CCP positivity strongly predicted RA progression (median-unbiased OR, 237.0; 95% CI, 18.7-3004.8; P < .001), with an 87.5% (7/8) positive predictive value. Elevated RF levels correlated significantly with overall rheumatological disease (P = .04) and specifically RA (P = .03). No meaningful correlations emerged between RF levels and age, erythrocyte sedimentation rate, C-reactive protein, or HBsAg status. Conclusions: Asymptomatic RF positivity carries a substantial 2-year risk (15.9%) for developing rheumatic conditions, predominantly RA and Sjögren disease. Anti-CCP positivity and elevated RF titers are strong predictors of progression. Regular clinical follow-up may enable earlier detection and intervention, though larger prospective studies are needed.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →